With the expansion of oral treatment options, adherence is also becoming a stronger driver in prescribing decisions. The competitive landscape for PNH has seen significant shifts, particularly ...

with growing consensus that all PNH patients should be on a complement or factor inhibitor, regardless of disease burden. With the expansion of oral treatment options, adherence is also becoming a ...

EPYSQLI® (eculizumab-aagh) is now available to patients living with difficult-to-treat rare diseases like paroxysmal ...

Bkemv is being offered at 10% off Soliris, and Epysqli is offered at 30% below Soliris. Both biosimilars treat several of the ...

Vanrafia (atrasentan) is the first drug in the selective endothelin A receptor antagonist (ERA) class to be cleared in the US ...

It is estimated that between 20% and 50% of PNH patients treated with C5 inhibitors have anaemia that may require blood transfusions, so there is a need for new treatment options. Apellis’ C3 ...

Q4 2024 Earnings Call Transcript March 31, 2025 Omeros Corporation beats earnings expectations. Reported EPS is $-0.54, ...